Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734

Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...